Edgen Stock·Sep 19 2025, 23:10戻る
戻る
Johnson & Johnson Bolsters Outlook with Oncology Approval and Strategic U.S. Investments
Edgen Stock·Sep 19 2025, 23:10
[1] Jim Cramer on Johnson & Johnson: “Very Rare Triple-A Balance Sheet” and Recent Positive Developments[2] Johnson & Johnson's FDA-Approved Bladder Cancer Therapy Inlexzo and Its Strategic Market Implications - AInvest[3] Johnson & Johnson Continues U.S. Investment with $2 Billion Commitment to Enable Manufacturing at State-Of-The-Art North Carolina Facility | MarketScreener